H
2142
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Hbm Holdings Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +47% compared to the Hang Seng (Hong Kong)'s +5% growth.
Stocks Performance
2142 vs Hang Seng (Hong Kong)
Performance Gap
2142 vs Hang Seng (Hong Kong)
Performance By Year
2142 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hbm Holdings Ltd
Glance View
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
